Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.
The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs.
In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
Company Details
- Employees
- 256
- Address
- 151 W 42nd St, 15th Floor,switzerland
- Industry
- Biotechnology
- Website
- http://www.roivant.com
- Keywords
- Pulmovant.
- HQ
- New York, New York
Roivant Questions
Roivant's website is http://www.roivant.com
Roivant's LinkedIn profile is https://www.linkedin.com/company/roivant
Roivant has
256 employees.
View email and phone details for 256
employees at Roivant.
Roivant's industry is
Biotechnology
Roivant's top competitors are
Pulmovant,
Vertex Pharmaceuticals,
Strive,
Ptc Therapeutics, Inc.,
Springworks Therapeutics,
Travere Therapeutics,
Priovant Therapeutics,
Qvt Financial Lp,
Vantai,
Immunovant.
Roivant's categories are Biotechnology
